Related Experiment Video
Updated: Aug 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Antiretroviral therapy in HIV-1 infected children
Rakesh Lodha1, Amit Upadhyay, S K Kabra
1Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Insights
Nevirapine-based antiretroviral therapy (ART) is a feasible and effective treatment for children with HIV-1 in resource-limited settings. This affordable regimen shows significant improvements in growth parameters and CD4 counts, aiding in pediatric HIV management.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Highly active antiretroviral therapy (HAART) is often inaccessible to children with HIV in developing nations.
- Limited data exists on cost-effective treatment regimens, such as those using nevirapine and two nucleoside reverse transcriptase inhibitors.
Purpose of the Study:
- To evaluate the feasibility and outcomes of nevirapine-based antiretroviral therapy in HIV-1 infected children in a resource-poor setting.
- To assess the impact of this regimen on growth parameters and CD4 counts.
Main Methods:
- A retrospective study of HIV-1 infected children receiving a 3-drug nevirapine-based ART regimen for at least three months.
- Regular follow-up included monitoring complications, anthropometry (weight for height, BMI), and CD4 counts.
Main Results:
- Twenty-six children (mean age 68.5 months) were followed for a mean of 19.7 months.
- Statistically significant improvements were observed in weight for height and body mass index.
- Mean CD4 counts showed a trend of improvement, although with considerable variability.
Conclusions:
- Nevirapine-based ART is a feasible treatment option for children with HIV-1 in resource-limited environments.
- The therapy demonstrates positive effects on growth parameters, crucial for pediatric HIV management.
- While generally well-tolerated, potential complications like skin rash and pancreatitis require monitoring.
Abstract:
Highly active antiretroviral therapy is beyond reach of most HIV-infected children in developing countries. There is paucity of data on more affordable regimens such as ones based on nevirapine and 2 nucleoside reverse transcriptase inhibitors. We report our experience with the use of antiretroviral therapy in children with HIV-1 infection at a tertiary care hospital in north India. The study subjects were HIV-1 infected children, who were receiving 3-drug antiretroviral therapy for a period of three or more months. The children were regularly followed up for any complications, changes in anthropometry, and changes in CD4 counts. The mean age of children at diagnosis (n=26; 22 boys) was 68.5 +- 33.4 months. These children were followed up for a mean of 19.7 +- 18.7 months. Twenty four children received nevirapine based regimen. There was statistically significant improvement in weight for height and body mass index on follow up. The mean CD4 count changed from baseline (n=24) of 584.3 +- 685.9 mm3 to 614.4 +- 455.7 mm3 (n=15) at last follow up. One child developed minor skin rash in the initial two weeks of starting nevirapine. One child developed pancreatitis. We conclude that administration of nevirapine based ART for HIV-1 infected children is feasible in resource poor setting. There is improvement in growth parameters with use of this therapy.
Related Concept Videos
Retrovirus Life Cycles
Respiratory Syncytial Virus Disease
Inhibitors of Virion Maturation and Assembly
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Size and Structure of Viral Genomes

